Navigation Links
Rigel Announces Fourth Quarter and Year End 2010 Financial Results
Date:3/1/2011

clusive worldwide license agreement with AZ for fostamatinib, that was fully recognized as revenue in 2010, as well as $25.0 million in milestone payments earned from AZ for the initiation of the phase 3 clinical trial program with fostamatinib in patients with RA and the completion of the transfer of the fostamatinib open label extension study to AZ.

As of December 31, 2010, Rigel had cash, cash equivalents and available for sale securities of $177.3 million, compared to $133.3 million as of December 31, 2009.  Rigel expects to end 2011 with approximately $105.0 million in cash, cash equivalents and available for sale securities, which is expected to be sufficient to fund operations into 2013.

"2010 was a significant growth year for Rigel due to our successful collaboration with AstraZeneca and their launch of the OKSIRA global phase 3 clinical trial program with fostamatinib," said James M. Gower, chairman and chief executive officer of Rigel. "We are now concentrating on furthering the development of our next clinical projects, that include a novel oral JAK3 inhibitor intended for the treatment of transplant rejection and a different JAK3 inhibitor in an ophthalmic formulation intended for the treatment of Sjogren's autoimmune-related dry eye," he added. "We expect both of these programs to enter phase 1 clinical studies in late 2011."

Pipeline/Program Update

As of March 2011, Rigel has seven programs in its development pipeline that are in varying stages of clinical or preclinical studies.  The two most advanced programs are licensed to pharmaceutical partners: AZ has initiated the OSKIRA phase 3 clinical trial program with fostamatinib in patients with RA; and R343 (an inhaled syk inhibitor for chronic asthma) is currently in phase 1 with Pfizer. AZ has announced that they are on target to file a new drug application with the U.S. Food and Drug Administration in 2013 for fostamatinib in RA. Pfizer has informed Rigel that i
'/>"/>

SOURCE Rigel Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Rigel Announces Initiation of Phase 1 Clinical Trial of R343 for Allergic Asthma by its Partner Pfizer
2. Rigels R788 Demonstrates Significant Improvement in Rheumatoid Arthritis in Phase 2 Clinical Study
3. Rigel Announces Initiation of Phase 1 Clinical Trial of R348 for Rheumatoid Arthritis, Psoriasis and Other Immune Disorders
4. Rigels R788 Shows Preclinical Activity in Type 1 Diabetes Model
5. Rigels R788 Slows Progression of Murine Lupus in Preclinical Studies
6. Rigel to Host Conference Call to Discuss Preliminary Phase 2 Study Results of R788 in Lymphoma
7. Rigels R788 Phase 2a Results Published in Arthritis and Rheumatism
8. Rigel Expects R788 Partnership After Phase 2b Clinical Trials Results
9. Shareholder Class Action Filed Against Rigel Pharmaceuticals, Inc. by the Law Firm of Barroway Topaz Kessler Meltzer & Check, LLP
10. Rigel Commences Phase 2 Trial of R788 in Peripheral T-Cell Lymphomas
11. Rigel to Host Conference Call to Discuss Results of Its Phase 2b TASKi2 Clinical Trial of R788 in Rheumatoid Arthritis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/28/2015)... , April 28, 2015   GenSpera, Inc. ... Patent and Trademark Office has issued U.S. Patent ... portfolio claiming numerous compositions for the company,s prodrugs ... (PSA).  GenSpera is developing a ... a powerful cytotoxin isolated from the poisonous plant, ...
(Date:4/28/2015)... , April 28, 2015  Unfors RaySafe, the ... new radiation Survey sensor aimed at expanding the RaySafe ... X2 Survey sensor is the easiest and fastest solution ... It is the latest addition to the continually expanding ... to perform leakage and scatter measurements in diagnostic X-ray ...
(Date:4/28/2015)... 28, 2015 /CNW/ - The group representing the living victims ... left a two-hour meeting with Health Canada officials in ... Health Canada announced a $180 million support package for ... weeks after the Health Canada announcement and five months ... the victims, the group representing Canada,s ...
Breaking Medicine Technology:GenSpera Granted New Patent for Prodrugs Activated by Prostate Specific Antigen 2Unfors RaySafe, a Fluke Biomedical company, unveils a new Survey sensor for the RaySafe X2 2Thalidomide Victims Gravely Concerned by Health Canada's Silence 2
... July 28, 2011 /PRNewswire/ -- ... and stabilization, and the US Army Medical Research Institute ... a Cooperative Research and Development Agreement (CRADA) to develop ... The two organizations will collaborate on the ...
... Inc. (NYSE: HRC ), announced financial results for ... its outlook for 2011. Adjusted earnings per diluted share increased ... earnings per diluted share in the fiscal third quarter decreased ... the prior year, and net income declined to $2 million ...
Cached Medicine Technology:Biomatrica and USAMRIID Sign a CRADA for the Development of New Technologies Applicable for Ambient Stabilization of Clinical and Biological Samples 2Biomatrica and USAMRIID Sign a CRADA for the Development of New Technologies Applicable for Ambient Stabilization of Clinical and Biological Samples 3Hill-Rom Reports Fiscal Third Quarter Results; Updates 2011 Financial Outlook 2Hill-Rom Reports Fiscal Third Quarter Results; Updates 2011 Financial Outlook 3Hill-Rom Reports Fiscal Third Quarter Results; Updates 2011 Financial Outlook 4Hill-Rom Reports Fiscal Third Quarter Results; Updates 2011 Financial Outlook 5Hill-Rom Reports Fiscal Third Quarter Results; Updates 2011 Financial Outlook 6Hill-Rom Reports Fiscal Third Quarter Results; Updates 2011 Financial Outlook 7Hill-Rom Reports Fiscal Third Quarter Results; Updates 2011 Financial Outlook 8Hill-Rom Reports Fiscal Third Quarter Results; Updates 2011 Financial Outlook 9
(Date:4/28/2015)... 28, 2015 Foot and Ankle ... Stephen D. Palmer ( Annapolis and Clarksville Divisions ... podiatry at the Maryland Podiatric Medical Association meeting on ... State University in 1992 with a Bachelor of Arts ... participated in intercollegiate soccer, track and cross-country. He then ...
(Date:4/28/2015)... 28, 2015 Foundations Recovery Network (FRN), ... announce the rebranding of its Memphis based residential treatment ... Center will now be known as The Oaks at ... a stand of beautiful old Oak trees long regarded ... may be new, the commitment and dedication to helping ...
(Date:4/27/2015)... Medical Device Design Control , Implementing ... Enterprises**, June 16-17, 2015 – Chicago, IL , ... a facility today, would the design control system pass ... "maybe" or "no" … then very likely there is ... solution. , Take this important step. Enroll TODAY ...
(Date:4/27/2015)... NY (PRWEB) April 28, 2015 ... new white paper called “Website Anatomy 101.” ... paper discusses the necessary design elements for a ... emphasis on responsive design, user experience, search results ... the impact of a well-designed website on patient ...
(Date:4/27/2015)... 2015 A new type of festival is ... Science on Tap at the Science Museum of Virginia not ... adds science hops for a bold, new flavor. , The ... serves up the science behind these frothy beverages. Guests uncover ... look at the ingredients that go into beer with Original ...
Breaking Medicine News(10 mins):Health News:Foot and Ankle Specialists of the Mid-Atlantic, LLC Podiatrist Receives Maryland Podiatric Medical Association Outstanding Service Award 2Health News:Foundations Recovery Network Rebrands LaPaloma Treatment Center as The Oaks at LaPaloma 2Health News:FDAnews Announces: Medical Device Design Control: Implementing an Approach That Works, June 16-17, Chicago, IL 2Health News:FDAnews Announces: Medical Device Design Control: Implementing an Approach That Works, June 16-17, Chicago, IL 3Health News:FDAnews Announces: Medical Device Design Control: Implementing an Approach That Works, June 16-17, Chicago, IL 4Health News:Smith & Jones Publishes 2015 Website Design White Paper 2Health News:Science on Tap at the Science Museum of Virginia 2
... aid stop the spread of cancer cells. Researchers at the University of ... related to the well-known antibiotic tetracycline. In a series of experiments, they ... tumour less likely to spread throughout the body. ... ,COL-3 appears to ...
... who are obese in middle age have premature thickening of ... arteries// in the neck as a useful marker for the ... linings of the carotid arteries are thickened, then it's more ... ,In a new study, doctors in Texas looked at carotid ...
... to a new study it is observed ... newly diagnosed multiple myeloma patients when combined with ... Clinic in Rochester, Minn.// gave 60 newly diagnosed ... synthetic steroid dexamethasone. Results show 55 percent of ...
... to two new studies, reveal people with GERD, ... more likely than others without these conditions to ... quality.// Researchers from Pennsylvania State University selected more ... for sleep-related breathing disorders, to participate in the ...
... aged 40 or over has a lifetime risk of heart ... have high blood pressure. Heart failure is an increasing problem, ... the heart which makes it hard to pump blood around ... condition is very disabling. ,Researchers for the Framingham ...
... researchers suggest that the presence of proteins linked to ... with high blood pressure. Although we know that high ... still the case that not everyone with hypertension actually ... that inflammation could be the key to understanding this ...
Cached Medicine News:
The new ProteomeX Workstation enables the rapid set up, execution and analysis of multidimensional LC/MS methods, providing you with the best possible technique to characterize your complex proteomic...
Storage temperature: 2 - 8C, linearity: 0 - 700 mg/dL, expected values: 30 - 780 mg/dL. Available with calibrator and number of tests 110....
Alkaline phosphatase FS (DGKC new; 37C). For determination of alkaline phosphatase (ALP) in serum or plasma. For Hitachi 717. Controls: Trulab N and Trulab P....
For the direct colorimetric determination of alkaline phosphatase in human serum....
Medicine Products: